Biogen will test Anavex Life Sciences’ lead drug candidate, ANAVEX 2-73, in an oligodendrocyte precursor cell (OPC) differentiation assay.
The VENTANA PD-L1 (SP142) Assay was approved as a complementary diagnostic for Tecentriq immunotherapy.
ZURICH (Reuters) – Food group Nestle has taken a further step into the medicine business by signing a research collaboration agreement with a Swiss biotech company to develop an Alzheimer’s disease diagnostic test. Nestle’s second medical deal in a week underscores the commitment by the world’s largest packaged food company to the faster-growing, more profitable […]
SEOUL, KOREA and HILDEN, GERMANY–(Marketwired – Jul 8, 2015) – Seegene Inc. (KOSDAQ: 096530), today announced that it has entered into a worldwide collaboration agreement with QIAGEN N.V. (NASDAQ: QGEN) (Frankfurt Prime Standard: QIA) to develop and supply molecular diagnostic assays. Under the terms of the agreement, Seegene will develop and manufacture multiplex infectious disease […]